Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- 31 January 2012
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 48 (1), 85-93
- https://doi.org/10.1016/j.ejca.2011.10.014
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC TrialJournal of Clinical Oncology, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Clinical endpoints for drug development in prostate cancerCurrent Opinion in Urology, 2008
- Chemotherapy for the treatment of hormone-refractory prostate cancerInternational Journal of Clinical Practice, 2007
- Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patientsCancer, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals Of Oncology, 2007
- Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cellsThe Prostate, 2004
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and PainJournal of Clinical Oncology, 2003